Provided by Tiger Trade Technology Pte. Ltd.

Sana Biotechnology, Inc.

4.11
+0.17504.45%
Volume:1.49M
Turnover:6.01M
Market Cap:1.09B
PE:-4.26
High:4.18
Open:3.95
Low:3.82
Close:3.93
52wk High:6.55
52wk Low:1.26
Shares:266.37M
Float Shares:168.00M
Volume Ratio:0.88
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9636
EPS(LYR):-1.1553
ROE:-96.11%
ROA:-23.90%
PB:5.60
PE(LYR):-3.55

Loading ...

Sana Biotechnology Files Form 3 Initial Beneficial Ownership Statement for CFO Brian Piper

Reuters
·
Yesterday

Sana Biotechnology Names Brian Piper Chief Financial Officer

Reuters
·
Feb 17

Sana Biotechnology (SANA) Valuation Check After J.P. Morgan Conference Cell Therapy Updates

Simply Wall St.
·
Jan 17

Bank of America Securities Reaffirms Their Buy Rating on Sana Biotechnology (SANA)

TIPRANKS
·
Jan 15

Sana Biotechnology Highlights Diabetes Cell Therapy Advances at Conference

TIPRANKS
·
Jan 15

Sana Biotechnology Is Maintained at Buy by B of A Securities

Dow Jones
·
Jan 07

Sana Biotechnology Achieves Potent In Vivo Gene Editing of Human Stem Cells Using Fusogen Technology

Reuters
·
Dec 08, 2025

Sana Biotechnology to Webcast Presentations at Major Investor Conferences

Reuters
·
Nov 25, 2025

Sana Biotechnology Q3 Operating Expenses USD 43.515 Million

Reuters
·
Nov 20, 2025

Quantum Computer That Could 'Hack Everyone's Crypto': Why Eric Jackson Is Betting On BTQ Technologies As His Next 100-Bagger

Benzinga
·
Nov 10, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zymeworks (ZYME), Sana Biotechnology (SANA) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Nov 10, 2025

Stock Track | Sana Biotechnology Plummets 5.68% Pre-Market as H.C. Wainwright Slashes Price Target

Stock Track
·
Nov 07, 2025

Sana Biotechnology Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 07, 2025

Sana Biotechnology’s Strategic Shift and Financial Positioning Justify Buy Rating

TIPRANKS
·
Nov 07, 2025

Sana Biotechnology Q3 Adj. EPS $(0.15) Beats $(0.18) Estimate

Benzinga
·
Nov 07, 2025

Sana Biotechnology Q3 net loss narrows

Reuters
·
Nov 07, 2025

Sana Biotechnology reports Q3 cash position of $153.1 million and focuses pipeline on type 1 diabetes and in vivo CAR T programs

Reuters
·
Nov 07, 2025

BRIEF-Sana Biotechnology Q3 Operating Expenses USD 43.515 Million

Reuters
·
Nov 07, 2025

Press Release: Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates

Dow Jones
·
Nov 07, 2025

Sana Biotechnology options imply 17.5% move in share price post-earnings

TIPRANKS
·
Nov 07, 2025